NCT01308996撤回不适用
A Prospective, Open Label, Randomized, Multicenter, Controlled Clinical Study of INFUSE® Bone Graft Used as an Alternative to Autogenous Bone Graft for Vertical Alveolar Ridge Augmentation
Medtronic Spinal and Biologics0 个研究点开始时间: 2012年4月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- 主要终点
- Osseous volumetric fill underneath the titanium mesh of edentulous sites in the posterior mandible.
研究概览
简要总结
The purpose of this study is to evaluate the INFUSE® Bone Graft as an alternative to autograft for bone formation in the back of the mandible (lower jaw) prior to placing dental implants.
详细描述
The purpose of this study is to evaluate INFUSE® Bone Graft as an alternative to autograft for alveolar ridge bone formation in the posterior mandible prior to dental implants. A subject must have a defect behind the canine of 2-4 teeth for at least 2 months and be a candidate for dental implants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has been edentulous for at least 2 months with an alveolar ridge defect affecting 2-4 teeth in the posterior mandible, posterior to the canine.
- •Has an alveolar ridge defect with a minimum starting height of 5 mm above the superior cortex of the inferior alveolar canal in the posterior mandible.
- •Is a candidate for dental implants (2-4 teeth) in the affected posterior mandibular alveolar ridge area.
- •Has a prosthodontic treatment plan in place.
- •Has no known condition that would interfere with collecting autogenous bone at either the tibia or the iliac crest for a bone grafting procedure.
- •Is 21-75 years of age (inclusive).
- •If female of childbearing potential, has a negative urine pregnancy test, is not lactating, and agrees not to become pregnant for at least 12 months after surgery.
- •Is able to comply with all study-related procedures, including exercising good oral hygiene.
- •Is able to provide written informed consent.
排除标准
- •Has bilateral alveolar ridge defects requiring simultaneous augmentation or a second augmentation planned during the course of the study.
- •Has an active infection at the planned augmentation site.
- •Has active periodontal disease of Grade III or higher.
- •Has had a dental extraction procedure at the planned augmentation site within the 2 months prior to Day
- •Has had a soft tissue graft at the planned augmentation site within less than 2 weeks of Screening.
- •Is expected to require any additional bone graft material (e.g., allograft and xenograft) at the planned augmentation site in addition to the investigative treatment or autogenous bone, as determined by the investigator prior to surgery.
- •Has a history of a failed alveolar ridge augmentation procedure.
- •Has a pathology finding that would either compromise a bone grafting procedure or interfere with obtaining quantitative measurements from postoperative CT scans.
- •Is an insulin-dependent diabetic.
- •Has an overt or active systemic infection, such as human immunodeficiency virus (HIV), bacteremia, or hepatitis C virus (HCV).
- •Has a planned augmentation site in the area of a resected or extant tumor.
- •Has presence of an active malignancy or prior history of malignancy (except for basal cell carcinoma of the skin).
- •Is actively using any nicotine-containing products such as, but not limited to, smoking and chewing tobacco, nicotine patch, nicotine gum, etc. within 2 weeks prior to Screening.
- •Is alcohol or drug dependent, as determined by the investigator.
- •Is taking medications or having treatment known to have an effect on bone metabolism, such as, but not limited to:
- •calcitonin within the past 6 months;
- •fluorides for 30 days or more within the past 12 months;
- •cumulative use of oral bisphosphonates for less than 5 years within the past 6 months;
- •cumulative use of oral bisphosphonates for 5 years or more;
- •any previous use of intravenous bisphosphonates;
- •chronic tetracycline (e.g., ongoing within the past month) or tetracycline analogs within the past 12 months;
- •estrogen replacement therapy within the past 2 months; or
- •methotrexate within the past 12 months.
- •Has a disease that affects bone metabolism, such as:
- •congenital connective tissue disease (e.g., Ehlers-Danlos syndrome, osteogenesis imperfecta);
- •hyperthyroidism; or
- •hyperparathyroidism.
- •Has a history of autoimmune disease (e.g., systemic lupus erythematosus, dermatomyositis, rheumatoid arthritis, etc.).
- •Has any previous exposure to any recombinant BMPs of either human or animal extraction.
- •Has a known history of prior exposure to silicone or injectable collagen implants.
- •Has a known hypersensitivity or allergy to collagen or protein pharmaceuticals (e.g., monoclonal antibodies or gamma globulins).
- •Has a known hypersensitivity or allergy to titanium.
- •Has a history of allergy to bovine collagen products.
- •Has chronic or acute renal failure
- •Has chronic or acute liver failure.
- •Has received treatment with an investigational therapy (drug, device, and/or biologic) within 30 days prior to bone graft implantation surgery or such treatment is planned during the 12-month period following the study surgery.
- •Has any condition that in the judgment of the investigator would place the subject at undue risk or interfere with the results of the study.
研究组 & 干预措施
Autogenous bone graft
Active Comparator
干预措施: Autogenous bone graft from tibia or iliac crest (Procedure)
INFUSE® Bone Graft
Experimental
干预措施: INFUSE® Bone Graft (Device)
结局指标
主要结局
Osseous volumetric fill underneath the titanium mesh of edentulous sites in the posterior mandible.
时间窗: 210 days
次要结局
- Pain level at the surgical site, as well as at the donor site (if applicable).(210 days)
- Ability to place dental implants(210 days)
- Histological evaluation (percent vital bone)(210 days)
- Surgical failure rate(210 days)
- Adverse Events(210 Days)
研究者
相似试验
终止
3 期
INFUSE®Bone Graft in Transforaminal Lumbar Interbody Fusion for Degenerative Disease of Lumbosacral SpineLumbar Spine DegenerationNCT01415908Medtronic Spinal and Biologics15
终止
3 期
Tibial Delayed Healing Pivotal Clinical TrialTibial Delayed HealingNCT01016067Medtronic Spinal and Biologics23
招募中
不适用
A Post Market Surveillance on INFUSE Bone GraftIntervertebral Disc DegenerationSpinal FusionLumbar Disc DiseaseNCT05299762Medtronic Spinal and Biologics600
已完成
不适用
INFUSE® Bone Graft/ PEEK Interbody Spacer/ Anterior Cervical Plate Pivotal Clinical TrialDegenerative Disc DiseaseNCT00485173Medtronic Spinal and Biologics224
Unknown
1 期
Novel Therapy of PAD by Combined Transplantation of BMCsPeripheral Arterial DiseaseNCT00411840Heinrich-Heine University, Duesseldorf100